Correlation between hematocrit and the risk of common human cancers: results of a 1999-2020 observational survey and Mendelian randomization analysis.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-04-03 DOI:10.1080/17474086.2025.2486381

Guo-Sheng Li, Tao Huang, Jing-Xiao Li, Jun Liu, Xiang Gao, Guan-Qiang Yan, Nuo Yang, Hua-Fu Zhou

{"title":"Correlation between hematocrit and the risk of common human cancers: results of a 1999-2020 observational survey and Mendelian randomization analysis.","authors":"Guo-Sheng Li, Tao Huang, Jing-Xiao Li, Jun Liu, Xiang Gao, Guan-Qiang Yan, Nuo Yang, Hua-Fu Zhou","doi":"10.1080/17474086.2025.2486381","DOIUrl":null,"url":null,"abstract":"Background: Previous studies have underscored the significance of hematocrit (HCT) in different tumors. However, further research is needed to explore its causal relationship with various tumors.Research design and methods: A retrospective analysis and a Mendelian randomization analysis were conducted on a sample of 3,580,275 samples to investigate the causal relationships between high HCT levels and the risks of developing the 15 prevalent malignant tumors. Additionally, using an in-house cohort, Kaplan-Meier curves were utilized to examine the relationship between HCT levels and the prognosis of patients with prostate cancer (PCa).Results: An elevated HCT level was identified as a protective factor against six types of cancers, including PCa (odds ratio [OR] < 1.000, p < 0.05), and a risk factor for cervical cancer, melanoma, and non-melanoma skin cancer (OR > 1.000, p < 0.05). A potential causal association was found between high HCT levels and decreased risks of developing PCa (OR = 0.887, p < 0.05) and breast cancer (OR = 0.893, p < 0.05). HCT was identified as a protective factor against PCa (p < 0.05).Conclusions: This study identified significant associations between HCT and nine tumors. HCT levels may serve as a protective factor against PCa.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-12"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2486381","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Previous studies have underscored the significance of hematocrit (HCT) in different tumors. However, further research is needed to explore its causal relationship with various tumors.

Research design and methods: A retrospective analysis and a Mendelian randomization analysis were conducted on a sample of 3,580,275 samples to investigate the causal relationships between high HCT levels and the risks of developing the 15 prevalent malignant tumors. Additionally, using an in-house cohort, Kaplan-Meier curves were utilized to examine the relationship between HCT levels and the prognosis of patients with prostate cancer (PCa).

Results: An elevated HCT level was identified as a protective factor against six types of cancers, including PCa (odds ratio [OR] < 1.000, p < 0.05), and a risk factor for cervical cancer, melanoma, and non-melanoma skin cancer (OR > 1.000, p < 0.05). A potential causal association was found between high HCT levels and decreased risks of developing PCa (OR = 0.887, p < 0.05) and breast cancer (OR = 0.893, p < 0.05). HCT was identified as a protective factor against PCa (p < 0.05).

Conclusions: This study identified significant associations between HCT and nine tumors. HCT levels may serve as a protective factor against PCa.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.